VectorY Therapeutics, a biotech company focusing on the development of gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, is collaborating with Wageningen University to develop novel baculovirus-based technologies for the production of safe and affordable AAV gene therapies.
 
VectorY, together with its partner Wageningen University, is making a strategic investment in the gene therapies of the future, by developing a production platform capable of successfully manufacturing safe products at a significant lower COGS. The collaboration represents an important step to enable the medical and economic feasibility of gene therapy for diseases that affect larger patient populations.
 
Under the terms of the collaboration, the Bioprocess Engineering and Virology Groups at Wageningen University and VectorY Therapeutics will work together on two projects. One will utilize the molecular toolbox to generate innovative stable baculovirus genome seeds for AAV production at large scale. The second will focus on the design and evaluation of an intensified and scalable baculovirus production process in bioreactors using state of the art bioprocess technologies.
 
“We are very pleased to be collaborating with VectorY to develop proprietary, next generation AAV expression systems and industry-leading bioprocessing capabilities,” said Monique van Oers, professor of Virology, Wageningen University.
 
“We are honored to partner with Wageningen University, a significant pioneer in the Baculovirology and Bioprocessing field. This partnership will further strengthen VectorY’s proprietary AAV production technologies for the development of Next Generation Gene Therapies,” added Alexander Vos, CEO VectorY Therapeutics.